express
purif
allel
b
burgdorferi
amplifi
polymeras
chain
reaction
use
primer
design
restrictionenzym
sequenc
compat
impact
plasmid
vector
new
england
biolab
forward
primer
ndei
restrict
site
underlin
revers
primer
xhoi
restrict
site
underlin
amplifi
vector
digest
ndei
xhoi
new
england
biolab
purifi
use
qiaquick
kit
qiagen
ligat
plasmid
vector
result
infram
gene
fusion
end
encod
intein
proteinspl
element
chitinbind
domain
encod
c
terminu
intein
allow
affin
purif
fusion
sequenc
dna
sequenc
confirm
construct
complet
proper
read
frame
ident
publish
sequenc
vlse
allel
transform
proteasedefici
escherichia
coli
strain
novagen
recombin
fusion
protein
express
follow
fresh
e
coli
coloni
inocul
l
luriabertani
broth
g
trypton
g
yeast
extract
difco
g
nacl
per
liter
contain
carbenicillin
novagen
cultur
incub
shake
reach
recombin
protein
synthesi
induc
addit
mm
boehring
mannheim
cultur
incub
h
cell
harvest
centrifug
cell
resuspend
ml
icecold
column
buffer
mm
trishcl
ph
mm
nacl
mm
edta
triton
sigma
supplement
mm
pefabloc
sc
boehring
mannheim
proteas
inhibitor
lyse
sonic
ice
cell
debri
remov
centrifug
h
g
clarifi
supernat
decant
purifi
use
impact
system
accord
manufactur
instruct
presenc
dithiothreitol
intein
undergo
specif
selfcleavag
releas
target
protein
chitinbound
intein
tag
result
singlecolumn
purif
target
protein
brief
small
column
pack
ml
chitin
bead
slurri
new
england
biolab
equilibr
column
volum
cvol
column
buffer
clarifi
lysat
load
wash
cvol
column
buffer
oncolumn
cleavag
intein
chitinbind
domain
initi
quick
flush
min
cvol
cleavag
buffer
mm
trishcl
ph
mm
nacl
mm
edta
contain
mm
dithiothreitol
new
england
biolab
column
cap
inhibit
flow
held
overnight
target
protein
elut
cvol
cleavag
buffer
aliquot
fraction
visual
discontinu
sdspage
acrylamid
resolv
gel
stack
eluat
dialyz
mm
trishcl
protein
concentr
determin
bicinchonin
acid
assay
pierc
purifi
store
igg
kelisakelisa
assay
condit
optim
multifactori
titrat
reagent
describ
jacobson
down
immulon
ii
microtit
plate
dynex
technolog
coat
ng
carbon
buffer
mm
mm
ph
cover
held
h
well
wash
time
mm
tri
hcl
mm
tri
base
ph
mm
nacl
mm
kcl
tween
tbst
follow
addit
block
buffer
mm
nacl
mm
tri
hcl
ph
tween
fetal
bovin
serum
hyclon
plate
held
min
room
temperatur
rt
wash
serum
sampl
dilut
block
buffer
ad
duplic
well
plate
incub
min
rt
well
wash
mg
goat
igg
alkalin
antibodi
kirkegaard
perri
laboratori
block
buffer
ad
plate
incub
min
rt
final
wash
substrat
mgml
pnitrophenyl
phosphat
sigma
carbon
buffer
b
mm
mm
ph
ad
well
optic
densiti
nm
immedi
measur
use
biotek
shake
elisa
plate
reader
softwar
biotek
instrument
optic
densiti
nm
record
interv
cours
min
result
report
mean
reaction
veloc
plate
shaken
cycless
measur
igm
kelisath
igm
kelisa
perform
describ
igg
kelisa
modif
microtit
plate
coat
ng
carbon
buffer
goat
igm
alkalin
antibodi
kirkegaard
perri
laboratori
dilut
mg
block
buffer
peptid
synthesisth
peptid
cmkkddqiaaamvlrgmakdgqfalk
synthes
louisiana
state
univers
medic
center
core
laboratori
new
orlean
fmoc
method
peptid
biotinyl
amino
terminu
nhydroxysuccinimid
biotin
bioaffin
system
purifi
reversephas
highpressur
liquid
chromatographi
column
mm
peptid
composit
verifi
matrixassist
laser
desorpt
flight
malditof
mass
spectrometri
expect
masstocharg
ratio
mz
observ
amino
acid
analysi
peptid
igg
kelisafor
igg
kelisa
microtit
plate
well
coat
streptavidin
pierc
carbon
buffer
cover
held
h
well
wash
time
tbst
follow
addit
block
buffer
contain
biotinyl
peptidewel
plate
incub
h
rt
rotat
rpm
wash
serum
sampl
dilut
block
buffer
ad
duplic
well
plate
incub
h
rt
rotat
well
wash
block
buffer
contain
ng
goat
igg
alkalin
antibodi
kirkegaard
perri
laboratori
ad
plate
incub
h
rt
rotat
final
wash
pnitrophenyl
phosphat
mgml
sigma
carbon
buffer
b
ad
optic
densiti
well
read
immedi
nm
describ
peptid
pvvaespkkp
synthes
biotechnolog
core
facil
scientif
resourc
program
nation
center
infecti
diseas
cdc
atlanta
use
fmoc
chemistri
amino
terminu
derivat
sulfonhslcbiotin
pierc
introduc
spacer
peptid
biotin
malditof
mass
spectrometri
demonstr
expect
product
expect
mz
observ
igm
peptid
kelisath
kelisa
igm
respons
perform
describ
peptid
kelisa
modif
peptid
dilut
goat
igm
alkalin
antibodi
dilut
block
buffer
control
standard
slope
calibrationfor
given
antigen
kelisa
microtit
plate
contain
human
serum
control
duplic
rang
reactiv
nonreact
highli
reactiv
control
standard
perform
given
plate
plot
slope
control
serum
sampl
mean
slope
control
serum
sampl
plate
assay
number
refer
plate
depend
assay
regress
line
fit
data
result
slope
intercept
use
calibr
individu
test
slope
plate
coeffici
determin
comput
measur
fit
regress
duplic
calibr
slope
averag
averag
consid
compar
subsequ
receiveroper
characterist
roc
analysi
standard
calibr
scheme
may
describ
formal
follow
let
xi
j
jth
sampl
ith
plate
let
ci
k
repres
kth
control
sampl
ith
plate
x
number
plate
plate
fit
linear
model
ci
kbimici
kei
k
ci
k
mean
kth
control
plate
ith
ei
k
error
term
numer
valu
bi
mi
model
obtain
least
squar
analysi
statist
comput
perform
use
splu
profession
insight
follow
standard
sampl
valu
xi
j
calibr
valu
si
j
use
si
jxi
jbimi
test
perform
area
roc
curv
auc
perform
assay
compar
use
nonparametr
roc
curv
analysi
mani
function
roc
analysi
splu
written
doug
mahoney
beth
atkinson
mayo
clinic
rochest
mn
avail
http
wwwmayoeduhsrsfunchtml
auc
comput
associ
confid
interv
ci
use
method
delong
et
al
auc
indic
perfect
diagnost
accuraci
cutoff
point
select
confid
intervalscutoff
point
classifi
specimen
posit
determin
fix
specif
determin
valu
base
empir
roc
curv
maxim
sensit
ci
result
sensit
comput
use
bootstrap
method
platt
et
al
take
account
true
specif
sensit
test
unknown
ci
test
sensit
clinic
class
specimen
comput
use
method
wilson
ci
singleantigen
parallel
comparisonsw
compar
result
singleantigen
kelisa
test
use
method
may
johnson
addit
singl
test
result
consid
parallel
see
whether
combin
result
produc
gain
perform
serum
sampl
score
posit
parallel
test
react
posit
either
test
score
neg
result
neg
comparison
perform
made
possibl
singl
parallel
result
clinic
group
comparison
sensit
test
test
b
parallel
test
also
made
use
method
may
johnson
account
correl
test
consid
provid
signific
improv
test
test
b
significantli
higher
sensit
either
b
without
significantli
lower
specif
statist
comparison
base
type
error
rate
twotier
serolog
testingserum
sampl
test
algorithm
recommend
cdc
sampl
test
presenc
igm
igg
antibodi
firststep
elisa
vida
vitek
sampl
posit
equivoc
reactiv
analyz
separ
igm
igg
western
immunoblot
marblot
mardx
diagnost
interpret
criteria
use
western
immunoblot
test
publish
elsewher
twotier
result
sampl
obtain
cdc
largevolum
refer
collect
obtain
archiv
data
human
serum
panel
sampl
serum
plasma
specimen
use
evalu
diagnost
accuraci
kelisa
tradit
analysi
sampl
refer
collect
store
lyme
diseas
sampl
patient
met
cdc
surveil
case
definit
nation
report
lyme
diseas
tabl
summar
distribut
sampl
clinic
classif
tuft
new
england
medic
center
boston
provid
serum
sampl
seventyseven
patient
earli
lyme
diseas
includ
pair
acut
convalescentphas
sampl
addit
earli
sampl
acutephas
sampl
convalescentphas
sampl
unpair
pair
serum
sampl
patient
erythema
migran
em
case
accompani
clinic
evid
dissemin
infect
patient
patient
dissemin
infect
multipl
site
em
present
evid
dissemin
infect
patient
em
includ
headach
stiff
neck
arthralgia
describ
elsewher
patient
receiv
antibiot
therapi
start
date
first
serum
sampl
obtain
length
time
em
onset
report
patient
initi
medic
treatment
vari
week
distribut
durat
infect
permit
studi
time
cours
develop
seroreact
median
interv
collect
acut
convalescentphas
specimen
day
mean
interv
day
sd
day
rang
day
twenti
addit
sampl
patient
earli
neuroborreliosi
person
acut
earli
neurolog
diseas
obtain
antibiot
treatment
patient
mening
facial
palsi
radiculoneuropathi
remain
sampl
obtain
treat
patient
convalesc
present
sign
patient
treatment
mening
facial
palsi
radiculoneuropathi
patient
earli
neuroborreliosi
histori
em
fortynin
sampl
patient
lyme
arthriti
intermitt
object
swell
joint
sampl
obtain
antibiot
treatment
obtain
patient
joint
inflamm
despit
prior
antibiot
treatment
obtain
convalesc
eight
sampl
individu
latestag
neurolog
diseas
patient
encephalopathi
polyneuropathi
receiv
antibiot
therapi
em
andor
lyme
arthriti
previous
late
diseas
case
definit
requir
least
late
manifest
laboratori
confirm
infect
therefor
possibl
select
bia
toward
reactiv
sampl
discount
fortyon
serum
sampl
patient
lyme
diseas
cdc
largevolum
refer
collect
obtain
plasmapheresi
divis
vectorborn
infecti
diseas
dvbid
fort
collin
co
twentyseven
sampl
patient
em
skin
b
burgdorferi
infect
sampl
obtain
convalesc
antibiot
therapi
em
earli
neuroborreliosi
arthriti
except
specimen
patient
em
obtain
therapi
eightytwo
pair
serum
sampl
patient
cultureconfirm
earli
infect
acutephas
convalescentphas
sampl
obtain
divis
infecti
diseas
new
york
medic
colleg
valhalla
patient
treat
antibiot
day
acutephas
specimen
collect
median
day
onset
em
recal
patient
mean
day
sd
day
rang
day
convalescentphas
sampl
obtain
median
day
later
mean
day
sd
day
rang
day
final
lyme
diseas
serum
sampl
patient
lyme
arthriti
lyme
encephalopathi
obtain
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
bethesda
md
part
larg
blindcod
panel
potenti
crossreact
specimen
cdc
provid
serum
sampl
healthi
individu
sampl
nation
center
infecti
diseas
divis
aid
sexual
transmit
diseas
tuberculosi
atlanta
specimen
dvbid
fourteen
sampl
obtain
peopl
resid
area
lyme
diseas
endem
ny
serum
sampl
patient
evid
autoimmun
diseas
spirochet
infect
lyme
diseas
test
one
hundr
specimen
posit
antinuclear
antibodi
patient
clinic
diagnosi
rheumatoid
arthriti
sampl
obtain
cdc
collect
atlanta
serum
sampl
patient
syphili
primari
syphili
secondari
syphili
earli
latent
syphili
late
latent
syphili
latent
diseas
unknown
durat
found
reactiv
treponema
pallidum
immobil
assay
obtain
world
health
organ
collabor
center
refer
research
treponematos
univers
california
lo
angel
sampl
patient
presumpt
tickborn
relaps
fever
found
posit
elisa
antibodi
b
hermsii
wholecel
sonic
antigen
obtain
cdc
serum
bank
dvbid
blood
sampl
obtain
cultur
case
found
posit
spirochet
caus
relaps
fever
five
pair
acut
convalescentphas
serum
sampl
patient
leptospirosi
obtain
moniz
research
center
oswaldo
cruz
foundat
brazilian
ministri
health
salvador
bahia
brazil
final
remaind
blindcod
panel
provid
niaidnih
includ
serum
sampl
anticardiolipin
antibodi
antinuclear
antibodi
rheumatoid
factor
reaction
rapid
plasma
reagin
test
patient
multipl
sclerosi
antigen
propertiesth
gene
minu
leader
sequenc
clone
impact
vector
ndei
site
allow
translat
code
sequenc
contain
vectorderiv
residu
attach
n
terminu
ctermin
xhoi
site
result
residu
leugluprogli
attach
protein
cleavag
purif
purifi
shown
figur
level
impur
detect
coomassi
blue
stain
test
performancefirst
test
perform
data
report
singleantigen
kelisa
igg
igm
igg
igm
compar
result
serolog
analys
tabl
subsequ
combin
test
result
best
diagnost
accuraci
tabl
discuss
perform
igg
kelisafor
standard
control
curv
igg
kelisa
mean
sd
calibr
slope
examin
roc
analysi
result
auc
ci
figur
specif
select
ci
cutoff
point
posit
sampl
slope
sensit
lyme
diseas
serum
sampl
regardless
clinic
present
patient
sampl
obtain
ci
result
indistinguish
serolog
test
tabl
lowest
sensit
observ
patient
acut
em
patient
singl
em
site
constitut
sign
yet
develop
antibodi
sensit
patient
patient
sign
dissemin
infect
well
em
seroposit
increas
subset
patient
earli
acut
lyme
diseas
interv
onset
em
first
serum
sampl
collect
known
sensit
detect
igg
antibodi
patient
serum
collect
within
week
onset
em
ci
figur
howev
dramat
increas
test
sensit
acut
diseas
observ
second
week
ill
sensit
test
patient
serum
collect
week
onset
em
ci
figur
serum
sampl
individu
late
manifest
lyme
diseas
almost
uniformli
seroposit
test
sensit
patient
lyme
arthriti
late
neurolog
diseas
ci
ci
respect
falseposit
specimen
healthi
blood
donor
person
condit
lyme
diseas
distribut
among
potenti
crossreact
control
sampl
categori
tabl
perform
igm
kelisafor
standard
curv
igm
kelisa
mean
sd
roc
analysi
calibr
slope
gave
auc
ci
figur
specif
select
ci
cutoff
point
posit
sampl
slope
sensit
lyme
diseas
serum
sampl
ci
tabl
assay
detect
igm
antibodi
patient
sensit
ci
serum
collect
within
week
onset
em
figur
among
patient
serum
collect
week
onset
em
sensit
assay
ci
fals
posit
igm
test
cluster
categori
healthi
blood
donor
area
lyme
diseas
endem
subject
perform
igg
kelisafor
standard
curv
igg
kelisa
mean
sd
high
mean
correl
coeffici
small
standard
deviat
made
igg
test
reproduc
individu
kelisa
calibr
slope
analyz
roc
result
auc
ci
highest
valu
assay
studi
figur
specif
select
ci
cutoff
point
posit
sampl
slope
sensit
lyme
diseas
serum
sampl
ci
tabl
unlik
igg
antibodi
respons
signific
differ
seroposit
peptid
patient
local
dissemin
infect
vs
respect
sensit
detect
antibodi
patient
serum
collect
within
week
onset
em
ci
figur
sensit
assay
among
patient
serum
collect
within
week
onset
em
ci
fewer
posit
result
found
assay
peptid
kelisa
statist
significantli
sensit
ci
assay
whole
recombin
antigen
use
ci
detect
exposur
b
burgdorferi
convalescentphas
serum
sampl
distinct
limit
observ
test
statist
significantli
lower
sensit
detect
antibodi
patient
earli
neurolog
diseas
sensit
ci
vs
ci
igg
assay
lower
sensit
also
observ
test
late
neurolog
sampl
result
statist
signific
perform
igm
kelisafor
standard
curv
igm
kelisa
mean
sd
calibr
slope
analyz
roc
curv
analysi
result
auc
ci
lowest
valu
assay
specif
select
ci
cutoff
point
posit
sampl
slope
cutoff
point
compar
high
result
crossreact
patient
serum
sampl
posit
antinuclear
antibodi
slope
rang
sensit
lyme
diseas
serum
sampl
ci
tabl
sensit
detect
antibodi
patient
serum
collect
within
week
onset
em
ci
sensit
igm
kelisa
figur
sensit
assay
patient
serum
collect
within
week
onset
em
ci
nearli
ident
sensit
igg
assay
perform
analysisth
specif
analysi
ci
sensit
lyme
diseas
serum
sampl
ci
statist
significantli
differ
igg
kelisa
igg
kelisa
tabl
result
clinic
group
combin
sensit
detect
antibodi
patient
serum
collect
within
week
onset
em
ci
observ
igg
test
figur
patient
serum
collect
within
week
onset
em
sensit
assay
ci
less
either
assay
detect
igg
antibodi
peptid
assay
differ
reveal
aggreg
dataalthough
statist
signific
differ
sensit
igg
kelisa
igg
kelisa
test
sampl
specif
set
import
differ
test
result
individu
specimen
fifti
lyme
diseas
serum
sampl
either
igg
kelisa
neg
igg
kelisa
posit
igg
kelisa
neg
igg
kelisa
posit
thirtysix
sampl
posit
test
neg
igg
kelisa
posit
test
neg
igg
kelisa
evalu
igg
igmwhen
result
kelisa
detect
igg
igm
antibodi
individu
analyz
parallel
overal
specif
decreas
ci
tabl
decreas
specif
accompani
increas
sensit
ci
ci
igg
test
alon
sensit
detect
exposur
b
burgdorferi
patient
serum
collect
within
week
onset
em
remain
ci
addit
igm
result
reflect
extrem
low
sensit
igm
test
alon
figur
sensit
parallel
test
patient
serum
collect
within
week
onset
em
ci
gain
result
perform
significantli
better
test
evalu
igg
igmwhen
igg
igm
test
result
consid
parallel
overal
specif
also
decreas
ci
tabl
increas
sensit
somewhat
greater
achiev
addit
igm
kelisa
find
combin
sensit
ci
sensit
detect
exposur
b
burgdorferi
patient
serum
collect
within
week
onset
em
ci
figur
sensit
parallel
test
patient
serum
collect
within
week
onset
em
ci
result
also
superior
test
evalu
igg
igma
test
consid
parallel
overal
specif
assay
decreas
ci
sensit
increas
ci
gain
analysi
abil
detect
antibodi
patient
serum
collect
within
week
onset
em
markedli
improv
ci
increas
time
sensit
test
sensit
patient
serum
collect
within
week
onset
em
ci
nearli
higher
test
period
acut
diseas
precisionth
control
serum
sampl
plate
plot
result
regress
line
view
measur
qualiti
mean
assay
sd
individu
assay
igm
kelisa
igg
kelisa
data
kelisa
accept
sampl
volum
suffici
repeat
analys
valu
still
indic
reason
good
fit
studi
reveal
sever
method
detect
antibodi
b
burgdorferi
equal
exceed
perform
test
evalu
use
panel
previous
collect
serum
specimen
us
patient
method
simpler
readili
standard
analysi
regulatori
clearanc
us
food
drug
administr
k
process
requir
manufactur
demonstr
new
test
substanti
equival
test
alreadi
approv
perform
kelisa
measur
igg
antibodi
peptid
equal
substanti
equival
serolog
test
specif
test
igg
respons
peptid
patient
neurolog
diseas
less
frequent
posit
igg
respons
result
test
find
must
examin
larger
number
sampl
especi
accord
prior
work
use
igg
endpoint
elisa
igm
antibodi
respons
peptid
score
parallel
either
igg
assay
specif
equival
wellstandard
test
sensit
entir
panel
lyme
diseas
serum
sampl
statist
significantli
better
analysi
base
primarili
improv
perform
earli
acut
diseas
sampl
patient
em
sensit
igg
igm
igg
igm
respect
compar
serolog
test
later
stage
diseas
studi
select
criteria
may
preclud
demonstr
improv
perform
test
laboratori
confirm
infect
part
case
definit
sampl
person
lyme
arthriti
sensit
parallel
test
serolog
test
earli
neurolog
diseas
sensit
kelisa
parallel
test
differ
statist
signific
late
neurolog
diseas
sensit
parallel
kelisa
use
analysi
although
sensit
igg
igm
lower
sampl
patient
late
neurolog
diseas
result
base
small
number
sampl
contrast
sensit
found
use
igg
endpoint
elisa
convalesc
earli
neuroborreliosi
lyme
arthriti
small
decreas
sensit
observ
test
score
parallel
test
patient
develop
em
resid
travel
area
lyme
diseas
endem
rash
recognit
remain
diagnost
method
choic
empir
antibiot
therapi
appropri
serolog
test
recommend
improv
sensit
kelisa
earli
acut
diseas
compar
test
high
specif
clinic
use
circumst
defin
formal
pretest
probabl
lyme
diseas
patient
rash
typic
em
posit
serolog
test
result
support
diagnosi
lyme
diseas
high
specif
test
nevertheless
neg
test
result
patient
even
improv
test
sensit
may
reduc
probabl
lyme
diseas
suffici
rule
diagnosi
convalesc
antibiot
treatment
em
patient
sensit
igg
igm
kelisa
reach
cutoff
point
achiev
specif
individu
kelisa
establish
substanti
panel
control
sampl
control
healthi
blood
donor
person
seroposit
test
test
antinuclear
antibodi
rheumatoid
factor
anticardiolipin
antibodi
rapid
plasma
reagin
test
well
repres
control
panel
also
includ
sampl
patient
spirochet
diseas
leptospirosi
syphili
tickborn
relaps
fever
particularli
challeng
well
known
react
wholecel
antigen
b
burgdorferi
despit
larg
number
control
use
studi
desir
futur
studi
test
sampl
patient
wider
varieti
rheumatolog
neurolog
condit
within
differenti
diagnosi
lyme
diseas
sampl
patient
human
granulocyt
ehrlichiosi
includ
studi
could
rule
coinfect
b
burgdorferi
sampl
avail
specif
test
report
highest
observ
specif
test
gener
unpublish
studi
report
refer
laboratori
includ
gener
practic
test
standard
perform
score
interpret
immunoblot
sometim
difficult
qualiti
result
provid
physician
may
lower
best
achiev
furthermor
studi
use
singl
commerci
elisa
immunoblot
singl
manufactur
test
result
product
may
vari
prior
studi
dvbid
produc
evalu
recombin
gene
product
use
serodiagnost
antigen
use
cdc
largevolum
serum
panel
data
shown
protein
flaa
dbpa
rev
frequent
recogn
protein
becam
focu
kelisa
develop
effort
serolog
studi
lawrenz
et
al
liang
et
al
augment
interest
evalu
vlsebas
assay
larg
panel
serum
sampl
lyme
diseas
serum
sampl
cdc
largevolum
refer
panel
found
neg
igg
antibodi
next
screen
igm
reactiv
wholecel
antigen
b
burgdorferi
immunoblot
ospc
frequent
reactiv
protein
data
shown
find
consist
wellknown
abil
ospc
elicit
vigor
igm
respons
earli
lyme
diseas
furthermor
immunodomin
peptid
defin
c
terminu
ospc
substanti
conserv
sequenc
among
european
strain
b
garinii
examin
ospc
sequenc
deposit
genbank
confirm
extend
observ
mathiesen
et
al
epitop
littl
polymorph
particular
pkkpcooh
motif
invari
isol
b
burgdorferi
sensu
lato
medic
import
full
ctermin
sequenc
report
therefor
investig
whether
igm
respons
peptid
could
improv
perform
serolog
test
exposur
b
burgdorferi
sensu
stricto
unit
state
score
parallel
vlsebas
assay
igg
antibodi
studi
chose
kelisa
format
standard
endpoint
elisa
kelisa
inform
permit
superior
qualiti
assur
slope
kelisa
directli
proport
concentr
antibodi
sampl
wherea
optic
densiti
endpoint
assay
usual
serial
dilut
serum
may
perform
estim
antibodi
concentr
endpoint
assay
kelisa
slope
reaction
enzym
substrat
well
direct
measur
rel
concentr
antibodi
continu
scale
experiment
error
readili
reveal
kelisa
format
slope
reaction
well
linear
result
given
run
indic
error
laboratori
techniqu
pipet
variat
reagent
suppli
instrument
perform
addit
kelisa
system
allow
calibr
data
plate
plate
use
standard
curv
use
control
serum
sampl
control
duplic
plate
studi
calibr
correct
variabl
experiment
condit
ambient
temperatur
slope
control
plot
mean
control
slope
plate
similar
antigen
result
regress
line
serv
measur
assay
qualiti
yield
slope
intercept
adjust
sampl
raw
slope
calibr
slope
plate
compar
directli
high
degre
discrimin
posit
neg
sampl
achiev
kelisa
optim
condit
rapid
hydrolysi
chromogen
hightit
antibodi
sampl
produc
od
min
assay
describ
recommend
jacobson
down
import
shake
plate
read
ensur
uniformli
distribut
chromogen
roc
curv
analysi
use
examin
data
individu
kelisa
everi
cutoff
point
sampl
score
posit
neg
result
sensit
plot
preselect
specif
extract
correspond
cutoff
point
result
sensit
empir
roc
curv
cutoff
point
use
score
serum
sampl
posit
greater
equal
cutoff
point
neg
less
cutoff
point
predict
valu
posit
test
sharpli
decreas
small
reduct
test
specif
serum
sampl
patient
low
pretest
probabl
lyme
diseas
assay
million
test
perform
annual
number
falseposit
result
would
everi
reduct
test
specif
number
higher
total
number
lyme
diseas
case
identifi
nation
mandatori
report
system
given
year
measur
auc
give
insight
overal
use
assay
data
show
igg
kelisa
greater
auc
kelisa
region
greatest
biolog
interest
consid
ie
specif
curv
indistinguish
partial
auc
nearli
ident
kelisa
kelisa
slope
test
well
report
calcul
optic
densiti
valu
record
interv
cours
min
enzym
reaction
initi
stage
studi
optic
densiti
read
cours
min
use
calcul
slope
igg
kelisa
substanti
number
sampl
test
slope
calcul
use
first
read
min
result
compar
roc
analysi
obtain
read
min
use
data
shown
empir
roc
curv
auc
indistinguish
respect
basi
find
logist
benefit
shorter
read
time
use
min
data
collect
subsequ
assay
final
comparison
igg
kelisa
slope
serum
sampl
test
reveal
minor
increas
sensit
min
read
ci
compar
ci
data
disagr
test
outcom
observ
earli
convalesc
serum
sampl
neg
min
posit
min
four
found
posit
igm
kelisa
therefor
reduc
igg
sensit
overcom
parallel
analysi
sum
singleantigen
igg
kelisa
equal
perform
serolog
test
combin
test
score
parallel
outperform
test
base
primarili
result
obtain
earli
acut
diseas
best
test
igg
igm
igg
igm
improv
test
sensit
analysi
greatest
earli
acut
lyme
diseas
choic
whether
use
peptid
igg
kinet
assay
clearcut
ground
perform
alon
evid
sensit
detect
antibodi
serum
patient
neurolog
diseas
observ
must
verifi
larger
number
sampl
prospect
studi
assay
offer
advantag
peptid
commonli
protein
express
e
coli
name
compar
eas
synthesi
product
high
puriti
presum
lower
cost
high
assay
signaltonois
ratio
igg
igm
igg
igm
kelisa
fulli
autom
fairli
easili
standard
object
interpret
proper
comparison
perform
test
would
evalu
perform
use
serum
sampl
criteria
posit
deriv
end
prospect
studi
progress
assess
test
would
use
clinic
practic
